- Home
- CNMD vs AUPH Comparison
CNMD vs AUPH Comparison
Compare CNMD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- AUPH
- Stock Information
- Founded
- CNMD 1970
- AUPH 1993
- Country
- CNMD United States
- AUPH Canada
- Employees
- CNMD N/A
- AUPH N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CNMD Health Care
- AUPH Health Care
- Exchange
- CNMD Nasdaq
- AUPH Nasdaq
- Market Cap
- CNMD 1.7B
- AUPH 1.4B
- IPO Year
- CNMD 1987
- AUPH 1999
- Fundamental
- Price
- CNMD $51.32
- AUPH $12.51
- Analyst Decision
- CNMD Hold
- AUPH Strong Buy
- Analyst Count
- CNMD 5
- AUPH 3
- Target Price
- CNMD $59.80
- AUPH $12.00
- AVG Volume (30 Days)
- CNMD 318.6K
- AUPH 1.5M
- Earning Date
- CNMD 10-29-2025
- AUPH 11-06-2025
- Dividend Yield
- CNMD 1.59%
- AUPH N/A
- EPS Growth
- CNMD 12.82
- AUPH N/A
- EPS
- CNMD 3.54
- AUPH 0.42
- Revenue
- CNMD $1,326,244,000.00
- AUPH $260,111,000.00
- Revenue This Year
- CNMD $6.73
- AUPH $16.92
- Revenue Next Year
- CNMD $5.45
- AUPH $14.43
- P/E Ratio
- CNMD $14.19
- AUPH $29.12
- Revenue Growth
- CNMD 3.94
- AUPH 25.59
- 52 Week Low
- CNMD $46.00
- AUPH $6.55
- 52 Week High
- CNMD $78.00
- AUPH $12.90
- Technical
- Relative Strength Index (RSI)
- CNMD 43.70
- AUPH 60.23
- Support Level
- CNMD $50.21
- AUPH $12.18
- Resistance Level
- CNMD $53.58
- AUPH $12.90
- Average True Range (ATR)
- CNMD 1.63
- AUPH 0.40
- MACD
- CNMD -0.41
- AUPH -0.08
- Stochastic Oscillator
- CNMD 16.10
- AUPH 71.80
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.